title: [Supportive drugs for improved implant healing].
abstract: BACKGROUND
  Improvement of implant healing in orthopedic and trauma surgery serves to improve the life expectancy of the implant. Good primary stability by clamping is a prerequisite for secondary stability and for the actual integration and healing of the implant.
  
  
  RESULTS
  Possible causes of implant loosening are abrasive particles, which arrive at non-integrated implants at the unsealed prosthesis-bone interface and provoke a macrophage-mediated foreign body reaction, resulting in periprosthetic osteolysis. Numerous animal studies have already described the use of bisphosphonates to inhibit osteolysis induced by abrasion and secondary instability. In patients with total knee arthroplasty, a decrease in prosthetic migration under the influence of bisphosphonates could be shown. The stimulation of bone formation around the implants and the resulting implant healing was demonstrated both in animal experiments for bone morphogenetic proteins (BMP) and in case reports for intermittent parathyroid hormone administration.
  
  
  CONCLUSIONS
  By using supportive drugs, it is possible to achieve an improvement in the osseointegration of implants; thus, more rapid secondary stability and load-bearing are expected.
authors.affiliation: Orthopädische Klinik und Poliklinik, Universitätsmedizin Rostock, Doberaner Str. 142, 18057, Rostock, Deutschland. ralf.skripitz@med.uni-rostock.de.
authors.forename: R
authors.initials: R
authors.lastname: Skripitz
authors.affiliation: Themistocles Gluck Hospital, Ratingen, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Kurth
authors.affiliation: Bereich Endoprothetik/Orthopädie, Klinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinik Leipzig AöR, Leipzig, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Roth
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D006801:Humans; D007595:Joint Prosthesis / Q000009:adverse effects*; D010014:Osteolysis / Q000209:etiology* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D004164:Diphosphonates
keywords: Bisphosphonates; Bone morphogenetic proteins; Osseointegration; Osteolysis; Parathyroid hormone